Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: Results of a pooled analysis of six retrospective observational studies

Journal of Medical Economics

Volumn 16, Issue 9, 2013, Pages 1137-1145

  Xie, Lin ^a   Wei, Wenhui ^b   Pan, Chunshen ^c   Baser, Onur ^d  

^a STATINMED RESEARCH   (United States)

^b SANOFI   (France)

^c ProUnlimited   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hypoglycemia; Insulin glargine; Pharmacoeconomics; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISPOSABLE INSULIN PEN; DRUG DELIVERY DEVICE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; ICD-9-CM; INSULIN TREATMENT; INSULIN VIAL AND SYRINGE; MALE; MEDICAL DEVICE; MENTAL DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; RETINOPATHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; COST SAVINGS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SYRINGES;

EID: 84883020981     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.824458     Document Type: Article

References (27)

1. Marrero DG. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. Clin Cornerstone 2008;9:63-70
2. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-74 (Pubitemid 46213760)
3. Goodall G, Sarpong EM, Hayes C, et al. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009;9:19
4. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-56
5. Cuddihy RM, Borgman SK. Considerations for diabetes: treatment with insulin pen devices. Am J Ther 2011: published online July 15 2011, doi: 10.1097/MJT.0b013e318217a5e3
6. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(1 Suppl):S11-63
7. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
8. Ahré n B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
9. Quilliam BJ, Simeone JC, Ozbay AB, et al. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673-80
10. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
11. Bron M, Marynchenko M, Yang H, et al. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012;124:124-32
12. Hammer M, Lammert M, Mej́as SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
13. Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care 2008;14:25-30
14. Davis S, Wei W, Garg S. Clinical impact of initiating insulin glargine with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-52
15. Xie L, Wei W, Pan C, et al. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther 2011;28:1000-11
16. Du J, Wei W, Xie L, et al. Real-world outcomes of initiating two different basal insulin therapies via disposable pens among patients with type 2 diabetes in US employer-sponsored health plans. Value Health 2011;14:A476
17. Garg SK, Wei W, Cao Z, et al. Clinical and economic outcomes among employees or their dependents with type 2 diabetes initiating insulin glargine via disposable pen or vial. J Gen Intern Med 2012;27(2 Suppl):S99-574
18. Lin J, Ling J, Wei W, et al. Outcomes of initiating insulin glargine therapy with disposable pen or vial among patients with type 2 diabetes in a US managed care health plan. J Diabetes Sci Technol 2012;6:462-5, A1-A202
19. Baser O, Wei W, Baser E, et al. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ 2011;14:673-80
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
21. Zhao Y, Campbell CR, Fonseca V, et al. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-32
22. Simeone JC, Quilliam BJ. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database. Ann Pharmacother 2012;46:157-68
23. Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications 2012;26:399-406
24. Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med 2009;121:7-12
25. Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4
26. Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, et al. A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. Health Qual Life Outcomes 2011;9:83
27. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ 2002;28:52-60